Minian, Nadia
Mehra, Kamna
Lingam, Mathangee
Dragonetti, Rosa
Veldhuizen, Scott
Zawertailo, Laurie
deRuiter, Wayne K.
Melamed, Osnat C.
Moineddin, Rahim
Thorpe, Kevin E.
Taylor, Valerie H.
Hahn, Margaret
Selby, Peter
Funding for this research was provided by:
Public Health Agency of Canada and the Medical Psychiatry Alliance (1617-HQ-000045, 1617-HQ-000045)
Article History
Received: 27 September 2023
Accepted: 24 December 2023
First Online: 6 January 2024
Declarations
:
: Ethics approval was obtained from the Centre for Addiction and Mental Health Research Ethics Board (REB #119/2018) and all healthcare providers provided informed consent before participating in the interview. All experiments were performed in accordance with relevant guidelines and regulations (such as the Declaration of Helsinki).
: Not applicable.
: The authors declare that they have no conflicts of interests with respect to this manuscript; however some authors have general disclosures to report. NM reports receipt of funding from Canadian Institutes of Health Research, Canadian Cancer Society, and from the Discovery Fund of Centre for Addiction and Mental Health. WKD is a shareholder of Abbott Laboratories. PS reports receipt of funding from Canadian Institutes of Health Research, Canadian Cancer Society, Pfizer Inc., Pfizer Canada, and Ontario Lung Association. PS also reports that through an open-tender process, Johnson & Johnson, Novartis, and Pfizer Inc. are vendors of record for having provided smoking cessation pharmacotherapy for research studies at free or discounted rates. PS holds the Vice-Chair, Research and Giblon Professor in Family Medicine Research, a University Named Professorship at the University of Toronto. VT has done speaking engagements for Abbvie. MH has received Alkermes consultant fees.